Evaluation of the Enhanced Constrained Rod Casting Test for Hot Tearing of 7xxx Aluminium Alloys
Abstract
Abstract The enhanced constrained rod casting (ECRC) test has been validated mainly on narrow-freezing-range alloys such as A206 and A380, and its repeatability and interpretation for wide-freezing-range 7xxx Al–Zn–Mg–Cu alloys remain largely unreported. Here, four cast 7xxx alloys containing 0.081–0.232 wt.% Fe were used as a case series, with three independent ECRC trials per composition. Crack widths, fracture locations, contraction load and temperature were cross-examined against JMatPro–Kou calculations, backscattered-electron/energy-dispersive spectroscopy (BSE/EDS) quantification and elastic–viscoplastic numerical simulations. Fracture locations were highly repeatable—the column-end junctions of the short rods A and B fractured in all twelve castings (100%)—whereas the long-rod (C, D) fractures were dispersed. The all-rod hot-tearing susceptibility (HTS) gave means of 67.1 ± 6.7, 74.1 ± 3.8, 68.3 ± 7.9 and 62.7 ± 19.0 for the Base, #1, #2 and #3 alloys; the between-alloy differences were smaller than the casting-to-casting variability and not statistically significant (p = 0.730). The peak contraction load was far more repeatable and ranked alloy #1 highest (87.2 ± 3.2 N, p = 0.077), as did the Kou index of the measured compositions, whereas a Fe-only scan produced nearly invariant indices—showing that the differences originate from the multicomponent solidification path, not from Fe alone. The simulation reproduced the longest late-mushy-stage residence and highest…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.